New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness

Abstract excerpt

In non-small cell lung cancer (NSCLC), the most frequent oncogenic mutation in western countries is KRAS, which, however, remains no clinically approved targeted therapies. Recent progress on high biological heterogeneity including diverse KRAS point mutations, varying dependence on mutant KRAS, wide spectrum of other co-occurring genetic alterations, as well as distinct cellular status across the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer therapeutics and mechanisms
• Share to Lung Cancer Research Studies
• Share to Lung Cancer Treatments and Mutations